Search

Xanthe M Lam

from South San Francisco, CA
Age ~72
Get Report
Also known as:
Xanthe Lam Revocable Allen
Phone and address:
662 Orchid Dr, South San Francisco, CA 94080
(650) 553-4200
Related to:
Alexander A Wang, 52Ping Wang, 54Ha Lam, 80Wilson Lam, 43Muoi LamHenry H Lam
Connected to:
Abigail S Lam, 28Amer L Lam, 38Angelina Lam, 66Anh LamArnold Y Lam, 55Ba Lam, 70Bay V Lam, 62Berlin Lam, 36Bo O Lam, 63Brittni A Lam, 32

Xanthe Lam Phones & Addresses

  • 662 Orchid Dr, South San Francisco, CA 94080 (650) 553-4200 (650) 624-5683
  • S San Fran, CA
  • Antioch, CA
  • San Francisco, CA
  • Daly City, CA
  • 67 Stoneybrook Ave, San Francisco, CA 94112

Work

Company: Genentech Oct 2013 Position: Principal scientist at genentech

Industries

Biotechnology

Resumes

Resumes

Xanthe Lam Photo 1

Senior Scientist

View page
Location:
South San Francisco, CA
Industry:
Biotechnology
Work:
Genentech
Principal Scientist at Genentech
Genentech
Senior Scientist

Publications

Us Patents

Controlled Release Microencapsulated Ngf Formulation

View page
US Patent:
6663899, Dec 16, 2003
Filed:
Jun 11, 1998
Appl. No.:
09/095911
Inventors:
Jeffrey L. Cleland - San Carlos CA
Xanthe M. Lam - San Francisco CA
Eileen T. Duenas - San Jose CA
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 964
US Classification:
424491, 424773, 424641, 424625, 424630, 424646, 424650, 424611, 424602, 424682
Abstract:
NGF microencapsulation compositions having controlled release characteristics, preferably with increased stability, for the NGF component, particularly human recombinant NGF (ârhNGFâ) are provided that yield enhanced stability of NGF for use in promoting nerve cell growth, repair, survival, differentiation, maturation or function. Methods for making and using such compositions are also provided.

Protein Formulation

View page
US Patent:
6685940, Feb 3, 2004
Filed:
Mar 14, 2001
Appl. No.:
09/809511
Inventors:
James Andya - Millbrae CA
Jeffrey L. Cleland - San Carlos CA
Chung C. Hsu - Los Altos Hills CA
Xanthe M. Lam - San Francisco CA
David E. Overcashier - El Granada CA
Steven J. Shire - Belmont CA
Janet Yu-Feng Yang - San Mateo CA
Sylvia Sau-Yan Wu - San Francisco CA
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39395
US Classification:
4241331, 422 40, 514 2, 514 23, 514 53
Abstract:
A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.

Protein Formulation

View page
US Patent:
6821515, Nov 23, 2004
Filed:
Aug 25, 2000
Appl. No.:
09/648896
Inventors:
Jeffrey L. Cleland - San Carlos CA
Chung C. Hsu - Los Altos Hills CA
Xanthe M. Lam - San Francisco CA
David E. Overcashier - El Granada CA
Janet Yu-Feng Yang - San Mateo CA
Assignee:
Genentech, Inc. - South San Fancisco CA
International Classification:
A61K 39395
US Classification:
4241301, 4241381, 5303871
Abstract:
A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.

Stabilizing Formulation For Ngf

View page
US Patent:
6964947, Nov 15, 2005
Filed:
Jul 18, 2000
Appl. No.:
09/619059
Inventors:
Linda R. De Young - El Granada CA, US
Xanthe M. Lam - Daly City CA, US
Tue H. Nguyen - San Mateo CA, US
Michael F. Powell - San Francisco CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K038/18
US Classification:
514 12, 530399
Abstract:
Formulations are provided comprising NGF and acetate-containing buffer from pH 5 to 6 that provide enhanced stability of NGF for use in promoting nerve cell growth, repair, survival, differentiation, maturation or function.

Antibody Formulation

View page
US Patent:
6991790, Jan 31, 2006
Filed:
Nov 28, 2000
Appl. No.:
09/724868
Inventors:
Xanthe M. Lam - San Francisco CA, US
James Q. Oeswein - Moss Beach CA, US
Boonsri Ongpipattanakul - Bangkok, TH
Zehra Shahrokh - San Francisco CA, US
Sharon X. Wang - San Mateo CA, US
Robert P. Weissburg - Greenville DE, US
Rita L. Wong - San Mateo CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395
C07K 16/00
C07K 16/28
US Classification:
4241301, 4241411, 4241521, 4241541, 4241731, 53038873
Abstract:
A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of antibody not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4. 5 to about 6. 0, a surfactant and a polyol is described, along with uses for such a formulation.

Protein Formulation

View page
US Patent:
7060268, Jun 13, 2006
Filed:
May 2, 2003
Appl. No.:
10/428728
Inventors:
James Andya - Millbrae CA, US
Jeffrey L. Cleland - San Carlos CA, US
Chung C. Hsu - Los Altos Hills CA, US
Xanthe M. Lam - San Francisco CA, US
David E. Overcashier - El Granada CA, US
Steven J. Shire - Belmont CA, US
Janet Yu-Feng Yang - San Mateo CA, US
Sylvia Sau-Yan Wu - San Francisco CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395
C12P 21/08
C07K 16/18
US Classification:
4241301, 4241581, 4241761, 53038825, 5303893
Abstract:
A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.

Controlled Release Microencapsulated Ngf Formulation

View page
US Patent:
7163701, Jan 16, 2007
Filed:
May 20, 2003
Appl. No.:
10/442894
Inventors:
Jeffrey L. Cleland - San Carlos CA, US
Xanthe M. Lam - San Francisco CA, US
Eileen T. Duenas - San Jose CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 9/64
US Classification:
424491, 530399
Abstract:
NGF microencapsulation compositions having controlled release characteristics, preferably with increased stability, for the NGF component, particularly human recombinant NGF (“rhNGF”) are provided that yield enhanced stability of NGF for use in promoting nerve cell growth, repair, survival, differentiation, maturation or function. Methods for making and using such compositions are also provided.

Injection Vehicle For Polymer-Based Formulations

View page
US Patent:
7582311, Sep 1, 2009
Filed:
Oct 13, 2000
Appl. No.:
09/687951
Inventors:
Jeffrey L. Cleland - San Carlos CA, US
Xanthe M. Lam - South San Francisco CA, US
Franklin Okumu - Oakland CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 9/14
A61K 38/00
US Classification:
424489, 424488, 424490, 424497, 514 2, 514 8, 514 12, 514 54, 530324
Abstract:
The invention provides injection vehicles suitable for administering particulate suspensions, such as polymer-based formulations, as well as associated pharmaceutical formulations, articles of manufacture, and kits. Other aspects of the invention included methods for producing and administering pharmaceutical formulations. The injection vehicles of the invention are superior to conventional injection vehicles in that they include a pseudoplastic composition that improves injectability, which facilitates delivery of the desired dose. The injection vehicles of the invention also allow the use of smaller-bore needles than are usually necessary to inject polymer-based formulations, reducing the pain associated with injection of such formulations.
Control profile
Xanthe M Lam from South San Francisco, CA, age ~72 Get Report